These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

291 related articles for article (PubMed ID: 29998375)

  • 41. Breaking immunotolerance of tumors: a new perspective for dendritic cell therapy.
    Rolinski J; Hus I
    J Immunotoxicol; 2014 Oct; 11(4):311-8. PubMed ID: 24495309
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Integrating Next-Generation Dendritic Cell Vaccines into the Current Cancer Immunotherapy Landscape.
    Garg AD; Coulie PG; Van den Eynde BJ; Agostinis P
    Trends Immunol; 2017 Aug; 38(8):577-593. PubMed ID: 28610825
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Combined TLR stimulation with Pam3Cys and Poly I: C enhances Flt3-ligand dendritic cell activation for tumor immunotherapy.
    Lim SN; Kuhn S; Hyde E; Ronchese F
    J Immunother; 2012; 35(9):670-9. PubMed ID: 23090076
    [TBL] [Abstract][Full Text] [Related]  

  • 44. IFN-alpha in the generation of dendritic cells for cancer immunotherapy.
    Santini SM; Lapenta C; Santodonato L; D'Agostino G; Belardelli F; Ferrantini M
    Handb Exp Pharmacol; 2009; (188):295-317. PubMed ID: 19031032
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Activated dendritic cells delivered in tissue compatible biomatrices induce in-situ anti-tumor CTL responses leading to tumor regression.
    Verma V; Kim Y; Lee MC; Lee JT; Cho S; Park IK; Min JJ; Lee JJ; Lee SE; Rhee JH
    Oncotarget; 2016 Jun; 7(26):39894-39906. PubMed ID: 27223090
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Genetically modified dendritic cells in cancer therapy: implications for transfusion medicine.
    Foley R; Tozer R; Wan Y
    Transfus Med Rev; 2001 Oct; 15(4):292-304. PubMed ID: 11668436
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Manipulating dendritic cell biology for the active immunotherapy of cancer.
    O'Neill DW; Adams S; Bhardwaj N
    Blood; 2004 Oct; 104(8):2235-46. PubMed ID: 15231572
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Prophylactic vaccines are potent activators of monocyte-derived dendritic cells and drive effective anti-tumor responses in melanoma patients at the cost of toxicity.
    Bol KF; Aarntzen EH; Pots JM; Olde Nordkamp MA; van de Rakt MW; Scharenborg NM; de Boer AJ; van Oorschot TG; Croockewit SA; Blokx WA; Oyen WJ; Boerman OC; Mus RD; van Rossum MM; van der Graaf CA; Punt CJ; Adema GJ; Figdor CG; de Vries IJ; Schreibelt G
    Cancer Immunol Immunother; 2016 Mar; 65(3):327-39. PubMed ID: 26861670
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Fusion of CpG-ODN-stimulating dendritic cells with Lewis lung cancer cells can enhance anti-tumor immune responses.
    Du YC; Lin P; Zhang J; Lu YR; Ning QZ; Wang Q
    Tissue Antigens; 2006 May; 67(5):368-76. PubMed ID: 16671943
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Cancer-associated fibroblast-targeted strategy enhances antitumor immune responses in dendritic cell-based vaccine.
    Ohshio Y; Teramoto K; Hanaoka J; Tezuka N; Itoh Y; Asai T; Daigo Y; Ogasawara K
    Cancer Sci; 2015 Feb; 106(2):134-42. PubMed ID: 25483888
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Immune adjuvants as critical guides directing immunity triggered by therapeutic cancer vaccines.
    Schijns V; Tartour E; Michalek J; Stathopoulos A; Dobrovolskienė NT; Strioga MM
    Cytotherapy; 2014 Apr; 16(4):427-39. PubMed ID: 24280238
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Wnt Signaling Cascade in Dendritic Cells and Regulation of Anti-tumor Immunity.
    Suryawanshi A; Hussein MS; Prasad PD; Manicassamy S
    Front Immunol; 2020; 11():122. PubMed ID: 32132993
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Metabolism of Dendritic Cells in Tumor Microenvironment: For Immunotherapy.
    Peng X; He Y; Huang J; Tao Y; Liu S
    Front Immunol; 2021; 12():613492. PubMed ID: 33732237
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Tumor lysate-loaded Bacterial Ghosts as a tool for optimized production of therapeutic dendritic cell-based cancer vaccines.
    Dobrovolskienė N; Pašukonienė V; Darinskas A; Kraśko JA; Žilionytė K; Mlynska A; Gudlevičienė Ž; Mišeikytė-Kaubrienė E; Schijns V; Lubitz W; Kudela P; Strioga M
    Vaccine; 2018 Jul; 36(29):4171-4180. PubMed ID: 29895501
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Autologous Tumor Cell Lysate-Loaded Dendritic Cell Vaccine Inhibited Tumor Progression in an Orthotopic Murine Model for Hepatocellular Carcinoma.
    Wang Q; Luan W; Warren L; Kadri H; Kim KW; Goz V; Blank S; Isabel Fiel M; Hiotis SP
    Ann Surg Oncol; 2016 Dec; 23(Suppl 5):574-582. PubMed ID: 26786094
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Current state and perspectives of dendritic cell vaccination in cancer immunotherapy.
    Farkas A; Conrad C; Tonel G; Borbenyi Z; Kemeny L; Dobozy A; Nestle FO
    Skin Pharmacol Physiol; 2006; 19(3):124-31. PubMed ID: 16612139
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Rationale for the Combination of Dendritic Cell-Based Vaccination Approaches With Chemotherapy Agents.
    Truxova I; Hensler M; Skapa P; Halaska MJ; Laco J; Ryska A; Spisek R; Fucikova J
    Int Rev Cell Mol Biol; 2017; 330():115-156. PubMed ID: 28215530
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Dendritic cell vaccines for cancer treatment.
    Gabrilovich DI
    Curr Opin Mol Ther; 2002 Oct; 4(5):452-8. PubMed ID: 12435046
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Nuclear receptor expression patterns in murine plasmacytoid and conventional dendritic cells.
    Karthaus N; Hontelez S; Looman MW; van Spriel AB; Ansems M; Adema GJ
    Mol Immunol; 2013 Oct; 55(3-4):409-17. PubMed ID: 23597769
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [Dendritic cell-based cancer immunotherapy].
    Aruga A
    Nihon Rinsho; 2010 Jun; 68(6):1107-10. PubMed ID: 20535963
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.